Health & Medical · Week of Oct 26, 2026
Baystate integration and Abbott cancer test: the week in health
A hospital integration, a cancer MRD test launch and a Southeast Asia mental health push led a week otherwise filled with investor notices.
The largest operational news came from Baystate Health, which says it integrated Baystate Mercy Hospital, its joint venture affiliates and 45 medical group entities in Massachusetts on Nov. 1, 2026, and switched to a new Oracle Health Electronic Health Record system-wide. On the product side, Abbott launched a whole-genome sequencing version of its Oncodetect molecular residual disease test, and Healthcare Triangle said it is entering neurotechnology and AI-supported mental healthcare in Malaysia and Indonesia.
Much of the rest of the week was routine investor communication from medical technology companies. Accuray and TransMedics both reported equity inducement awards under NASDAQ listing rules, PAVmed scheduled a third-quarter business update call, and Boston Scientific confirmed its participation in Stifel's 2026 Healthcare Conference. MarketsandMarkets also issued a market forecast for patient registry software.
Baystate Health System
Baystate Health Welcomes Baystate Mercy Hospital into its Integrated Health System, Strengthening Regional Access to Care
Baystate Health says it integrated Baystate Mercy Hospital, its joint venture affiliates and 45 medical group entities in Massachusetts on Nov. 1, 2026, launching a new Oracle Health Electronic Health Record and the MyBaystate Health patient portal. The system says patients in Springfield, Chicopee and Agawam will keep the same care teams at the same locations, with no impact to insurance coverage, and that the Sister Caritas Cancer Center is now part of its cancer program.
Abbott
Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment
Abbott launched a next-generation Oncodetect molecular residual disease test using whole-genome sequencing and MAESTRO technology to detect traces of cancer during and after treatment. The company says the test tracks up to 5,000 patient-specific variants with a limit of detection below one part per million under high-end inputs.
Healthcare Triangle, Inc.
Healthcare Triangle Enters Neurotechnology AI Devices and Solutions for Southeast Asia
Healthcare Triangle says it is entering neurotechnology AI devices and solutions for Southeast Asia, starting with Malaysia and Indonesia, which it describes as home to more than 310 million people. The initiative combines neuroscience devices, professional education and AI-supported mental healthcare.
Accuray Incorporated
Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules
Accuray reported equity inducement awards, as required by NASDAQ Listing Rules, to Sofiane Laoussadi, its new Senior Vice President, Global Services & Solutions. The filing marks a leadership addition to the company's global services operation.
TransMedics Group, Inc.
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics, which works in organ transplant therapy for end-stage lung, heart and liver failure, announced inducement grants made on October 28, 2026, under NASDAQ Listing Rule 5635(c)(4). The disclosure is a standard notice tied to equity awards for new hires.
PAVmed Inc.
PAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026
PAVmed will hold a third quarter 2026 business update conference call and webcast on November 13, 2026, at 8:30 AM ET. The company describes itself as a commercial-stage medical technology firm working in medical devices, diagnostics and digital health.
Boston Scientific Corporation
Boston Scientific to participate in Stifel's 2026 Healthcare Conference
Boston Scientific will participate in Stifel's 2026 Healthcare Conference on Wednesday, November 11, 2026. Kenneth Stein, M.D., senior vice president and global chief medical officer, and Lance Bates, executive vice president, are listed among the company's participants.
MarketsandMarkets
Patient Registry Software Market worth $3.99 billion by 2031 - Exclusive Report by MarketsandMarkets™
MarketsandMarkets projects the patient registry software market will reach USD 3.99 billion by 2031 from USD 2.47 billion in 2026, a CAGR of 10.0%. The figures come from the research firm's own report.
This roundup is written with AI assistance from the press releases listed above, using only what they state. The releases are the companies' own announcements, not Today Parents reporting.